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Abstract
Background: Glaucoma is a complex, multifactorial disease characterised by the loss of retinal ganglion cells and their
axons leading to a decrease in visual function. The earliest events that damage retinal ganglion cells in glaucoma are
currently unknown. Retinal ganglion cell death appears to be compartmentalised, with soma, dendrite and axon changes
potentially occurring through different mechanisms. There is mounting evidence from other neurodegenerative diseases
suggesting that neuronal dendrites undergo a prolonged period of atrophy, including the pruning of synapses, prior to
cell loss. In addition, recent evidence has shown the role of the complement cascade in synaptic pruning in glaucoma
and other diseases.
Results: Using a genetic (DBA/2J mouse) and an inducible (rat microbead) model of glaucoma we first demonstrate that
there is loss of retinal ganglion cell synapses and dendrites at time points that precede axon or soma loss. We next
determine the role of complement component 1 (C1) in early synaptic loss and dendritic atrophy during glaucoma.
Using a genetic knockout of C1qa (D2.C1qa-/- mouse) or pharmacological inhibition of C1 (in the rat bead model) we
show that inhibition of C1 is sufficient to preserve dendritic and synaptic architecture.
Conclusions: This study further supports assessing the potential for complement-modulating therapeutics for the
prevention of retinal ganglion cell degeneration in glaucoma.
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Background
Glaucoma is a complex multifactorial disease character-
ized by the progressive dysfunction and loss of retinal
ganglion cells and associated visual field deficits. It
remains a leading cause of vision loss affecting 70
million people worldwide [1]. In spite of notable tech-
nical advances, the earliest neurodegenerative events
that injure retinal ganglion cells during glaucoma [1–5]
are unclear. Degeneration of the retinal ganglion cell dur-
ing glaucoma appears to be partially compartmentalized,
with different mechanisms influencing the soma, axon
and dendritic tree. In human glaucoma, early changes to
retinal ganglion cells have been observed both in the optic
nerve head, including axon transport deficits [6–9], as well
as in the retina with dendritic atrophy [10–12]. The pre-
cise relationship of axonal damage to events at the cell
soma and retinal ganglion cell synaptic connectivity has
been the focus of a number of recent studies in animal
models of glaucoma [13–16] in which dendritic remodel-
ling has been shown to precede gross cell loss. Recently,
we demonstrated retinal ganglion cell dendritic atrophy
during DBA/2J glaucoma and suggested that dendritic
remodelling may be an early feature of glaucoma [16].
However, the mechanisms by which these early retinal
ganglion cell changes occur are not known.
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It has been proposed that activation of immune re-
sponses may be key events that damage retinal ganglion
cells during early stages of glaucoma. Using a rat model of
ocular hypertension (based on the sclerosis of episcleral
vessels), Johnson et al. showed gene expression changes
with significant enrichment of immune response pathways
and cell proliferation pathways, among others [17]. The
exploration of gene expression at the level of the optic
nerve head confirmed immune cell responses and micro-
glial activation, in the absence of significant astrocyte acti-
vation [18]. Guo and colleagues extended this work by
showing an early immune cell response, coupled with
gene expression patterns, that suggested retinal ganglion
cell dysfunction and dendritic remodelling [19, 20]. Im-
mune cell and/or microglial activation may therefore be a
pertinent, early disease feature in animal models of glau-
coma. Early changes to microglia [17–29] and peripherally
derived immune cells [4, 30, 31] have been well docu-
mented in animal glaucoma models and in human glau-
coma [32–34], consistent with this scenario of early
immune activation.
The DBA/2 J mouse is a widely used model of chronic
glaucoma showing hallmark features of the human dis-
ease. In DBA/2 J mice, mutant alleles of two genes
(GpnmbR150X and Tyrp1b) cause iris pigment dispersion
that results in ocular hypertension in the majority of
eyes by 8 to 9 months of age. Glaucomatous damage is
usually present by 12 months, signified by the loss of
retinal ganglion cells and axonal degeneration within the
optic nerve [35], which appears to initiate at the optic
nerve head [2]. The interaction of multiple cell-types
residing within the optic nerve head and retina are
thought to be critical in glaucoma although the roles of
specific cell-types are not well understood [3, 36–39].
We have previously used microarray gene expression of
optic nerve head and retina tissue from pre-glaucomatous
(8.5 months old) and glaucomatous (10.5 months old)
DBA/2 J mice [3] in order to demonstrate that changes to
inflammatory pathways, including the endothelin pathway,
cell-adhesion pathways and the complement system occur
early in the disease. In particular, induction of genes
encoding proteins of the complement cascade was the
earliest identifiable molecular change in glaucomatous
DBA/2 J retinas [3]. DBA/2 J mice deficient for C1qa
show robust protection from glaucomatous retinal gan-
glion cell loss and optic nerve degeneration [3]. The com-
plement cascade has been heavily implicated in human
and animal models of glaucoma, has increased expression
in the eyes of patients with end stage glaucoma, and in
primate and murine glaucomatous eyes [30, 40–49].
The role of the complement cascade in glaucoma is
complex. In addition to its role in inflammatory signal-
ling, complement pathways play a critical role in synap-
tic development and pruning [46, 50–53]. During central
nervous system development neurons make many im-
mature synaptic connections, followed by the selective
elimination of those that are redundant. In the retinas of
C1qa–deficient mice, retinal ganglion cells show defect-
ive synaptic elimination with limited refinement of the
retinogeniculate pathway. TGF-β is thought to be im-
portant in the refinement process through activation/
regulation of the complement cascade in neurons,
microglia [51] or astrocytes [50]. The colocalization of
C1q, part of the initiating complex of the classical path-
way of the complement cascade, with synaptic markers
such as PSD95 early in glaucomatous pathogenesis [50]
supports the concept that complement activation under-
pins synapse elimination in glaucoma.
Here we determine the role of C1 in early synaptic loss
and dendritic atrophy during glaucoma. We quantified
synaptic and dendritic atrophy during early stages of
glaucoma using two models of ocular hypertension. We
demonstrate that synaptic and dendritic atrophy occur
prior to any detectable damage to the axon or soma in
both DBA/2 J glaucoma and in a rat model where ocular
hypertension (OHT) was induced using an injection of
magnetic microspheres [54]. Importantly, inhibiting C1
functions using either genetic ablation (DBA/2 J mutant
for C1qa) or pharmacological inhibition (C1 esterase in-
hibitor in the rat OHT model) was sufficient to preserve
dendritic and synaptic architecture. Taken together with
the strong protective effect of C1qa knockout in retinal
ganglion cell death and optic nerve damage, this sug-
gests that inhibition of C1 should be considered as a
therapeutic strategy for glaucoma.
Methods
Mouse strain, breeding and husbandry
Mice were housed and fed, as published [3], in a 14 h
light/10 h dark cycle with food and water available ad
libitum. All breeding and experimental procedures were
undertaken in accordance with the Association for Re-
search for Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic Research. The Institu-
tional Animal Care and Use Committee (IACUC) at The
Jackson Laboratory approved this study. The DBA/2 J
(D2, n (mice) = 24), DBA/2 J-Gpnmb+ (D2-Gpnmb+, n =
20), and D2.C1qa (n = 16) strains were utilized and have
been described in detail elsewhere [3]. We used D2-
Gpnmb+ mice as a control, non-glaucomatous substrain
of DBA/2 J [55].
Rat husbandry and IOP monitoring
Rat work was conducted in accordance with the Animals
(Scientific Procedures) Act 1986. Brown Norway rats
(Charles River, UK) were housed under a 12 h light/dark
cycle with IOP measured at the same time of day in
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order to reduce variation in IOP. Breeding diet (SDS,
RM3) and water were provided ad libitum.
Glaucoma induction and IOP monitoring in the rat
Baseline IOP for both eyes was established prior to glau-
coma induction and IOP measured 24 h after induction
and every 3 days thereafter. IOP was measured using a
rebound tonometer (TonoLab, Finland) calibrated for
use on the rat eye. Animals were awake and unrestrained
during measurement, requiring only topical 0.4 % oxybu-
procaine hydrochloride eye drops (Midoptic, UK). IOP
was taken as the average of 5 repeat readings. Glaucoma
was induced as described for the magnetic microbead
model [54]. Briefly, the left anterior chamber was injected
with 10 μl of bead solution (sterile ~4.5 μm diameter para-
magnetic microspheres, Invitrogen UK, in balanced salt
solution) using a 32-gauge needle and Hamilton syringe
(n = 19). Injections were conducted under isofluorane-
induced anaesthesia with topical 0.5 % chloramphenicol
(Mid Optic, UK) applied to the cornea. Beads were drawn
into the iridocorneal angle using a small handheld magnet
in order to block trabecular meshwork outflow and induce
OHT (n = 20). The right eye remained an un-operated,
normotensive (NT) control.
C1 inhibitor administration
C1 inhibitor (C1 esterase inhibitor; CINRYZE; Shire
(previously ViroPharma)) or vehicle only (PBS) was ad-
ministered to rats 24 h prior to induced ocular hyperten-
sion (OHT) and then once every 4 days for 16 days.
Intravitreal injections of 5 μl of C1 inhibitor (100 Units/
ml (n = 17)) or PBS (n = 10) were performed on the left
eye under isofluorane-induced anaesthesia.
DiOlistic labelling of flat mount retinas
The protocol for retinal dissection and DiOlistic label-
ling was identical for both mouse and rat eyes except
where stated otherwise. DiI and DiO coated tungsten
bullets were prepared as described previously using 8
mg DiI and 16 mg DiO (both Life technologies, US)
dissolved in 100 μl dichloromethane to 100 mg of tung-
sten particles (1.7 μm; Bio-Rad). Mice were killed by
cervical dislocation, their eyes enucleated and retinas
immediately dissected in chilled HBSS. For rats, a rising
concentration of CO2 was used, with cervical dislocation
confirming death. Retinas were dissected as described
above. Retinas were then flat mounted ganglion cell
layer (GCL) up on Millicell cell culture inserts (0.4 μm
pore diameter, Life technologies, US). Retinas were then
ballistically labelled with DiO/DiI bullets at a pressure of
120 psi using a Helios gene gun system (Biorad, US). 3.0
μm pore size cell culture inserts were placed between the
gun and retina to prevent aggregated particles over label-
ling the retina. The culture inserts were then placed in
Neurobasal-A media (Life technologies, US) containing 2
mM L-glutamate, 2 % B27 supplement and 1 % N2
supplement and incubated for 30 min at 37 °C, 4 %
CO2 to facilitate dye diffusion. Retinas were then fixed
in 4 % PFA for 30 min before mounting on glass slides
with Fluoromount and coverslips.
Immunofluorescent staining of retinal sections
The protocol for immunohistochemical staining of ret-
inal sections was identical for both mice and rats except
where stated otherwise. Mice were sacrificed by cervical
dislocation, their eyes enucleated and placed in 4 % PFA
ON. For rats, a rising concentration of CO2 was used,
with cervical dislocation confirming death. Following
this, eyes were cryoprotected in 30 % sucrose, frozen in
OCT and cryosectioned at 12 μm. Eyes from the follow-
ing number of animals (and central retina sections) were
used: (in mice [animals (sections)]; 4mo D2 n = 6[34], 9mo
D2 n = 3[25], 4mo D2-Gpnmb+ n = 9[36], 9mo D2-Gpnmb
+ n = 5[28], 4mo D2.C1qa n = 5[29], 9mo D2.C1qa n =
3[30]. Rats: normotensive n = 9[43], normotensive plus C1
inhibitor n = 3[49], OHT n = 3[38], OHT plus C1 inhibitor
n = 3[36]). Central retina sections were brought to RT for 1
h, permeabilized with 0.1 % Triton-X for 30mins, blocked
with 5 % chick serum in PBS and stained ON at RT in pri-
mary antibody (for mice; rabbit anti-PSD-95; 51-6900, Life
Technologies, USA, or goat anti-IBA1; ab5076, Abcam,
UK; for rats; rabbit anti-PSD-95; ab18258, Abcam, UK).
After primary antibody incubation, sections were washed 5
times in PBS, stained for 4 h at RT with secondary anti-
body (for mice; goat anti-rabbit AF488; Life Technologies,
USA, for rats; goat anti-rabbit AF555, Abcam, UK). Slides
were then washed a further 5 times with PBS, stained with
DAPI (mice) or Hoechst 33342 (rats) for 15mins, mounted
with fluoromount, coverslipped and sealed with nail-
polish. For PSD95 quantification in DBA/2 J mice and rats,
images of central retina showing the IPL and ONL were
collected under identical conditions on a Leica SP8 con-
focal microscope and Leica DM6000B respectively (image
area = 553.57 μm2). Fluorescent intensity of antibody stain-
ing was quantified using ImageJ. Three-dimensional recon-
struction of IBA1+ cells was performed using IMARIS.
Retinal ganglion cell morphological analysis
Retinas were imaged using either a Leica SP8 or Zeiss
LSM 510 confocal microscope with ×20 objective (mice:
4mo D2 n = 63, 9mo D2 n = 58, 4mo D2-Gpnmb+ n = 27,
9mo D2-Gpnmb+ n = 37, 4mo D2.C1qa n = 30, 9mo
D2.C1qa n = 52. Rats: normotensive n = 43, normotensive
plus C1 inhibitor n = 49, OHT n = 38, OHT plus C1 in-
hibitor n = 36). Z-stack imaged (slice thickness 1 μm) were
captured for mouse retinal ganglion cells and rat retinal
ganglion cells ensuring that the entire dendritic tree was
in frame. A number of RGC morphological features were
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measured using FIJI. Dendritic field area was measured by
connecting the outermost dendritic tips using the convex
polygon tool. The dendritic tree was traced and the mean
dendritic length calculated using the Neuron J plugin.
Sholl analysis was conducted using the bitmap Sholl ana-
lysis plugin for FIJI [56]. Statistical analysis was conducted
using SPSS 20 (IBM, US).
Classifying retinal ganglion cell subgroups
Retinal ganglion cells can be classified on the basis of their
dendritic tree and soma morphology. To account for any
bias that may arise from selective labelling of cells, we
classified retinal ganglion cells from our control groups
(in mice D2-Gpnmb+ and in rats, the normotensive group)
based on classifications set out by Sun et al. [57, 58].
There was no obvious bias in the cell types expected (in
mouse; our study (expected), RGCA 9 % (10 %), RGCB
38 % (30 %), RGCC 41 % (37 %), RGCD 13 % (23 %), in
rat; RGCA 20.9 % (17.5 %), RGCB 32.6 % (29.2 %),
RGCC 34.9 % (35.2.3 %), RGCD 11.6 % [18]). Once cells
start to degenerate classifying based on morphology
may lead to misrepresentation of cells at different
stages of disease. Given that our control groups
showed equal, unbiased sampling, we did not classify
disease susceptible DBA/2 J or D2.C1qa-/- retinal gan-
glion cells. As lamination is unlikely to drastically
change during disease, we confirmed that an even pro-
portion of ON/OFF/ON-OFF cells were present across
our samples (in mouse; ON/OFF/ON-OFF, D2-Gpnmb
+ 87 %/4 %/9 %, D2 86 %/7 %/7 %, D2.C1qa 86 %/6
%/8 %, in rat; normotensive 71 %/17 %/12 %, normo-
tensive plus C1 inhibitor 74 %/12 %/14 %, OHT 82
%/7 %/10 %, OHT plus C1 inhibitor 84 %/8 %/8 %).
This is further expanded on in the Discussion.
Axon labelling with PPD and grading of glaucomatous
damage
The processing of optic nerves and staining with para-
phenylenediamine (PPD) which darkly stains the axo-
plasm and myelin sheath of damaged axons has been
reported previously [59]. In brief, intracranial portions of
optic nerves were fixed in 4 % PFA at RT for 48 h, proc-
essed and embedded in plastic. A segment of optic nerve
from within a region up to 1 mm from the posterior sur-
face of the sclera was sectioned (1 μm thick sections)
and stained with PPD. Typically 30-50 sections are taken
from each nerve. Homology between sections is consid-
ered during grading. Optic nerves were analysed and
only eyes that had a corresponding nerve grade of ‘no or
early damage’ (i.e. less than 5 % axons damaged) were
selected in order to evaluate early disease events prior to
axonal damage.
Results
Synapse reduction precedes optic nerve damage and is
C1qa dependent
Dendrites degenerate prior to significant axon degener-
ation in DBA/2 J mice [16]. However, the factors that
drive this dendritic atrophy in glaucoma are not known.
Given the role of the complement cascade in synapse
loss during development and neurodegenerative diseases
[50], and the early induction of the complement compo-
nents in the inner plexiform layer of glaucomatous
retinas [3], we hypothesized that complement may medi-
ate both synapse loss and dendritic atrophy in glau-
comatous retinas. To test this, we first assessed the
synaptic density of the inner plexiform and ganglion cell
layer of 9 month-old DBA/2 J mice (an age at which
IOP elevation is established) using a synaptic marker,
PSD-95. To focus on very early stages of glaucoma, eyes
were selected that had no detectable signs of glaucomat-
ous axon damage (see Methods). Previous studies have
shown that at 9 months, axonal transport is intact in these
eyes [4, 16]. DBA/2 J eyes were compared to age matched
control eyes (D2.Gpnmb+) and pre-glaucomatous DBA/2 J
eyes (4 months prior to IOP increase). In both these con-
trol strains, at the ages selected, there was no detectable
axon damage.
To test the role of complement activation during synapse
loss in the IPL, we measured synaptic density using PSD-
95. Twelve-micron sections were labelled with anti-PSD-
95 antibody and DAPI (to demarcate the boundaries of the
inner plexiform layer). At a young, pre-glaucomatous age
(4 months old) there was no difference in labelling inten-
sity in the IPL between D2.Gpnmb+ and DBA/2 J mice
consistent with similar synaptic development in these
genotypes. However, in 9 months old, DBA/2 J eyes with
no discernible optic nerve disease or RGC loss there was a
significant reduction in synaptic integrity (20 % compared
to 4 months old DBA/2 J, P < 0.001 and 18 % compared to
aged matched D2.Gpnmb+, P < 0.001) (Fig. 1). Given that
C1QA expression increases in the IPL early in glaucoma
[3, 50] and that DBA/2 J mice deficient in C1qa are
protected from optic nerve degeneration, we tested the
role of C1qa in synapse degeneration in DBA/2 J glau-
coma. In D2.C1qa-/- eyes, PSD-95 labelling intensity did
not reduce significantly with age (6 % 4-9 months com-
parison, P = 0.26) (Fig. 1a) consistent with a role for C1qa
in glaucomatous synapse elimination. There was no sig-
nificant difference in outer plexiform layer (OPL) PSD-95
intensity (data not shown). Supporting a possible involve-
ment of retinal microglia in early retinal ganglion cell syn-
apse loss, high-resolution imaging combined with 3D
reconstruction revealed high-resolution rendered images
of IBA1+ microglia containing PSD-95 (Fig. 1c) support-
ing the concept that activated microglia phagocytose C1q
tagged synapses in the early stages of DBA/2 J glaucoma.
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Early RGC dendrite loss is preserved in D2.C1qa-/- retinas
We next explored whether complement C1q deficiency
prevents dendritic atrophy in DBA/2 J glaucoma. Den-
dritic integrity was quantified in DiOlistically labelled
retinas from 9 month-old DBA/2 J, D2.Gpnmb+, and
D2.C1qa-/- eyes with no detectable optic nerve damage.
Two hundred and sixty seven cells were identified as ret-
inal ganglion cells (confirmed by the presence of an axon
running in the nerve fibre layer towards the optic disc)
imaged at 40× and then compressed to give a 2D image
for quantification. Dendritic architecture was assessed by
total dendritic field area, total dendritic length, and den-
dritic complexity [60]. At 4 months of age, there were
no significant differences in any of these phenotypes
between mice of each genotype. By contrast, 9 month-
old DBA/2 J mice had a significant reduction in retinal
ganglion cell dendritic integrity compared to control
D2.Gpnmb+ mice (significant reduction in dendritic field
area (P < 0.01), and trending decreases in AUC and total
dendritic length which do not reach significance), con-
sistent with earlier work on non-glaucomatous retinas at
12 months of age [16].
Dendritic atrophy was not present in D2.C1qa-/- ret-
inal ganglion cells, the dendritic trees of which were
unchanged compared to the RGCs from D2.Gpnmb+
control mice (Fig. 2), confirming the critical importance
of C1qa and its protein product C1q for early dendritic
atrophy in DBA/2 J glaucoma. In addition there was no
Fig. 1 DBA/2 J mice exhibit synapse loss early during glaucoma pathogenesis which is absent in D2.C1qa-/- retinas. a. Immunohistochemical labelling
(PSD-95, red) to demonstrate synaptic integrity in 9 months old DBA/2 J retinas. All eyes shown had no significant retinal ganglion cell or axon loss.
Using C1qa mutant DBA/2 J mice (D2.C1qa-/-) we explored whether synaptic pruning was present in these retinas. At 4 months D2.Gpnmb+, DBA/2 J
and D2.C1qa-/- retinas show comparable synapse density (a, top row). By 9 months, there is significant synapse loss in retinas of DBA/2 J mice that is
absent in retinas of either D2.Gpnmb+ or D2.C1qa-/- (a, bottom two rows). b. The degree of PSD-95 labelling is shown. The region of interest is marked
(white boxes in upper row). c. Rendered confocal images show PSD-95 localisation within IBA1+ microglia in the IPL of DBA/2 J mice. Inset shows a
higher resolution image of a region of interest (white rectangle, d). d. Inset from C showing PSD95 engulfed by IBA1+ microglia, inset within d (white
rectangle) shows PSD95 and DAPI only. Scale bar = 50 μm (a), 5 μm (c) and 1 μm (d and inset), error bars = SEM, *** = P < 0.001, GCL = ganglion cell
layer, IPL = inner plexiform layer, INL = inner nuclear layer
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significant change in soma sizes across groups (data not
shown). A panel of representative, DiOlistically labelled
retinal ganglion cells is shown in Fig. 3.
C1 inhibitor protects retinal ganglion cells from dendritic
and synaptic atrophy
To further evaluate the role of C1q in dendrite and syn-
apse integrity in glaucoma, we used an experimentally
induced bead-model of ocular hypertension in the rat. In
this model paramagnetic beads (~4.5 μm in diameter)
are injected into the anterior chamber and pulled into
the trabecular meshwork under the influence of an ex-
ternal magnetic field to generate sustainable increases in
IOP [54] (Fig. 4). As with the DBA2J mouse, a reduction
in PSD95 labelling indicated significant synapse loss in
the IPL with retinal ganglion cell dendritic atrophy in
glaucomatous eyes compared to the control, (un-injected),
contralateral eyes (Figs. 5, 6 and 7). There was no signifi-
cant difference in OPL PSD-95 intensity (data not shown).
To evaluate the role of C1q in synaptic loss and den-
dritic atrophy in the rat model, and to assess therapeutic
benefit of pharmacologic inhibition of the C1 complex, we
administered human C1 inhibitor intraviterally 1 day prior
to the induction of ocular hypertension and then at 4 day
intervals for a period of 28 days for those animals with
sustained elevation in IOP. C1 inhibitor-treated eyes were
significantly protected from RGC dendritic and synaptic
atrophy compared to normotensive (NT) eyes. No signifi-
cant dendritic or synaptic atrophy was observed in treated
normotensive eyes (that received C1 inhibitor without
Fig. 2 C1qa plays a role in dendritic pruning early during glaucoma pathogenesis. We tested whether C1qa has a role in dendrite remodelling
using mice deficient in C1qa (D2.C1qa-/-). a Area under the curve (AUC) of the Sholl analysis (at 4 months of age (b), and at 9 months of age (d))
shows a decrease in dendritic complexity in DBA/2 J retinal ganglion cells that is absent in D2.Gpnmb+ and D2.C1qa-/- retinas. This is paralleled in
both the retinal ganglion cell dendritic field area (c) and total dendritic length (e). Error bars = SEM, ** = P < 0.01, *** = P < 0.001
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OHT) (Figs. 5, 6 and 7). In addition there was no signifi-
cant change in soma sizes across groups (data not shown).
Importantly, the C1 inhibitor had no significant effect on
the IOP profile (Fig. 4). Collectively, our data support a
major role for C1 and the classical pathway of the comple-
ment cascade in dendritic and synaptic pruning during
early glaucoma.
Discussion
Multiple compartments of the retinal ganglion cell are
suggested to be impacted in glaucoma [61]. While the
optic nerve head is considered a primary and critical site
of damage in glaucoma [2, 6, 8, 9, 62] early damage may
also manifest at other locations including the retinal
ganglion cell soma, dendrites and synapses [3, 10–12,
16, 63–67]. In this study, we use both a genetic (DBA/2
J mice) and an inducible (rat bead) model of glaucoma
to show that significant changes occur to retinal gan-
glion cell synapses and dendrites prior to optic nerve
degeneration. This dendritic and synaptic atrophy is dis-
ease- but not age-related as there is no detectable atrophy
in age and strain matched, non-glaucomatous controls
(D2.Gpnmb+). At this stage of the disease there is no dam-
age as detectable by PPD staining of the optic nerve or ret-
inal ganglion cell loss, predicting that observed effects [68]
might be subtle. It cannot be ruled out that there was
regional bias in the DiOlistic labelling in areas of the ret-
ina that are resistant to damage or contain retinal ganglion
cells of varying morphologies. This seems unlikely given
that DiOlistic labelling is diffuse (typically 5-20 cells per
retina labelled evenly across the retina) and random. The
preferential damage or loss of selective types of retinal
ganglion cells has been investigated previously in the
DBA/2 J mouse model, with neither cell type specific
loss of dendritic morphology or somal shrinkage appar-
ent [13, 69]. In addition, we have previous shown that
genetic labelling of retinal ganglion cells introduces an
inherent bias that might misrepresent cells at different
stages of the disease in DBA/2 J glaucoma [16]. However,
new, unbiased genetic tools that allow the visualization of
specific retinal ganglion cell subtypes are being developed
and provide scope for further investigation once available
across mouse strains and in the rat [68]. These early
changes to retinal ganglion cell structures in the retina are
consistent with the early loss of pattern electroretino-
gram (PERG) that occurs in DBA/2 J mice [2, 70]. Since
dendritic integrity is essential for the efficient gener-
ation of action potentials in the retinal ganglion cells,
we suggest that dendritic degeneration may be an im-
portant contributor to the reduced PERG signal in early
glaucoma [71, 72].
Determining the timing of changes to retinal ganglion
cell compartments in the retina in relation to axonal
changes in the optic nerve head in humans and animal
models will be important to fully understand the earliest
drivers of glaucoma. Although early soma and axon loss
have been reported in 9 months old mice in other col-
onies [73], this is not the general case in our DBA/2 J
colony [35]. However, in eyes with no significant optic
nerve damage (based on optic nerve damage assessment
Fig. 3 Representative DiOlistic and tracings of mouse retinal ganglion cells. Retinal ganglion cells from D2.Gpnmb+, DBA/2 J and D2.C1qa-/- retinas were
DiOlistically labelled to analyse dendritic morphology. Top row: representative images and tracings from 4 month (left) and 9 month (right) D2.Gpnmb+
retinal ganglion cells. Centre row: representative images and tracings from 4 month (left) and 9 month (right) DBA/2 J retinal ganglion cells. Bottom row:
representative images and tracings from 4 month (left) and 9 month (right) D2.C1qa-/- retinal ganglion cells. Scale bar = 100 μm, white arrows = axon
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just behind the orbit) or axon transport disruption,
discrete and focal axon damage is observed in the glial
lamina region of the optic nerve head at this stage [2].
The extent of the changes to retinal ganglion cell synap-
ses and dendrites in the retina are greater than the num-
ber of focally damaged axons in the optic nerve head
suggesting synaptic and dendritic atrophy are amongst
the earliest pathological events in DBA/2 J glaucoma. To
explore whether this is exclusive to the DBA/2 J mouse
we also studied these changes in an inducible model of
rat ocular hypertension, showing dendritic atrophy in
eyes with consistent elevations in IOP but not in sham
treated, normotensive or contralateral eyes.
Since early synaptic and dendritic atrophy were associ-
ated with an increase in complement components in the
IPL [50] the complement pathway was a promising candi-
date for mediating early retinal ganglion cell degeneration.
The key finding in the present study is that early synaptic
and dendritic atrophy were prevented through inhibition
of the C1 complex, the initiating complex of the classical
complement pathway. D2.C1qa-/- mice developed the an-
terior segment changes that occur in normal DBA/2 J
mice with subsequent elevation in IOP [3]. Only a small
percentage of D2.C1qa-/- mice go on to develop optic
nerve degeneration and retinal ganglion cell loss [3]. At 9
months of age (prior to any retinal ganglion cell loss and
optic nerve degeneration) we could not discern any
significant reduction in retinal ganglion cell dendritic in-
tegrity or synapse number compared to age matched, con-
trol D2.Gpnmb+ retinas, i.e. DBA/2 J dendritic and
synaptic atrophy is prevented by C1qa deficiency. The
functional implications of this protective effect (e.g. if the
PERG is restored in DBA/2 J mice deficient in C1qa) have
yet to be elucidated.
Fig. 4 Ocular hypertension occurs in rat eyes treated with C1 inhibitor. a Average IOP over a 20 day time course. b Individual IOP recordings at
each day of measurement (0 = day 0, base line reading). Points represent an average of 5 readings per eye. Note that C1 inhibitor administration
does not significantly affect intraocular pressure. Error bars = StDev. *** = P < 0.001
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Given our findings in DBA/2 J glaucoma we sought to
test whether pharmacological inhibition of C1 could be
of therapeutic value in glaucoma. We demonstrate that
intravitreal administration of human C1 inhibitor prior
to and during the onset of OHT preserved dendritic and
synaptic integrity in eyes with sustained elevations in
IOP. Global genetic inhibition of C1 in the mouse pro-
tects all compartments of the retinal ganglion cell. It is
important to note that, C1 inhibitor treatment in the rat
did not protect the optic nerve, most likely reflecting the
reduced accessibility of the drug outside of the retina
(data not shown). This shows inhibiting complement in
the retina is sufficient to protect dendrites and synapses
even whilst axon degeneration is occurring. Our results fur-
ther support compartmentalised changes in the retinal gan-
glion cell possibly due to independent, but not necessarily
mutually exclusive, intraocular pressure-related events in
the retina and optic nerve head. Studies employing the
systemic administration of C1 inhibitors would clarify the
protective effects of C1 inhibition in neural compartments
outside the retina.
Complement activation has been shown in human
and animal models of glaucoma [3, 49, 74], as well as
in other chronic neurodegenerative diseases such as
Alzheimer’s disease [75–82]. The classical pathway of
the complement cascade is heavily implicated in glau-
coma, and in DBA/2 J mice deficient in C1qa there is a
significant decrease in retinal ganglion cell loss and
optic nerve degeneration compared to regular DBA/2 J
mice [3]. The complement cascade is activated by the
classical, alternative or lectin pathways, converging at
the cleaving of C3 into effector fragments that can
modulate immune response such as chemo-attraction,
phagocytosis or cell lysis. The precise mechanisms by
which C1qa or the C1 complex contribute to glau-
comatous retinal ganglion cell damage is not known
but the opsonisation of synapses for removal by micro-
glia [46, 50, 51, 53, 83], seems one likely route. C3-
independent roles for the C1 complex have been also
identified. For instance, C1q can bind apoptotic cells
to promote their phagocytic uptake by myeloid-derived
macrophages. C1q can also bind the frizzled receptor
Fig. 5 Ocular hypertensive rat eyes exhibit early inner plexiform layer synapse loss which is absent in C1 inhibitor treated eyes. Administration of
a commercial FDA approved C1 inhibitor reduced synapse loss. a Representative images of rat retinas labelled with PSD-95 to show synapses.
b Analysis of synaptic density. NT = normotensive eyes, sham control, OHT = ocular hypertensive eyes. Scale bar = 50 μm, * = P < 0.05, *** = P < 0.001,
GCL = ganglion cell layer, IPL = inner plexiform layer, INL = inner nuclear layer
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Fig. 6 Inhibition of C1 prevents retinal ganglion cell dendrite pruning in ocular hypertensive rat eyes. To test dendrite loss in the rat bead model
of glaucoma we DiOlistically labelled retinal ganglion cells following an ocular hypertensive insult. There was a dramatic decrease in dendritic integrity
of retinal ganglion cells in ocular hypertensive eyes compared with normotensive eyes as assessed by Sholl analysis (a, area under the curve (AUC),
b, Sholl analysis). This is paralleled in both the retinal ganglion cell dendritic field area (c) and total dendritic length (d). NT = normotensive eyes, sham
control, OHT = ocular hypertensive eyes. Error bars = SEM, * = P < 0.05, ** = P < 0.01, *** = P < 0.001
Fig. 7 Representative DiOlistic and tracings of rat retinal ganglion cells. Retinal ganglion cells from normotensive eyes and ocular hypertensive eyes
were DiOlistically labelled to analyse dendritic morphology. Top row: representative images and Bottom row: tracings from normotensive (far left),
ocular hypertensive (centre left) normotensive (centre right), and ocular hypertensive (far right) retinal ganglion cells treated with C1 inhibitor. Scale
bar = 100 μm, white arrows = axon
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and modulate WNT signalling [84]. Components of the
C1 complex are up-regulated in multiple cell types in the
retina and optic nerve head during early stages of glau-
coma, particularly myeloid derived cells and retinal gan-
glion cells. However, the extrinsic or intrinsic factors that
induce or modulate complement induction are also not
known. In the brain, C1qa expression increase in IBA1+
cells and neurons with age, and C1qa deficiency can miti-
gate age-related cognitive decline [53, 85]. Therefore, the
complement cascade is playing multiple roles during dif-
ferent stages of glaucoma and further work is required to
elucidate them.
Conclusion
This study demonstrates in two different animal models of
glaucoma that early synaptic and dendritic atrophy is
dependent on C1QA, a component of the C1 complex of
the complement cascade. It provides further evidence for
the importance of complement activation in glaucoma, rais-
ing the possibility that complement-modulating therapeu-
tics could play a role in the prevention of retinal ganglion
cell damage.
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